Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference
Catalyst Pharmaceuticals (Nasdaq: CPRX) will present at the Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026 at 3:30 PM ET.
Rhea-AI Summary
Catalyst Pharmaceuticals (Nasdaq: CPRX) will present at the Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026 at 3:30 PM ET.
Management led by President and CEO Rich Daly will webcast the presentation; the webcast is available via the company investor website and a replay will be accessible for at least 30 days.
Positive
- None.
Negative
- None.
Details
News Market Reaction – CPRX
In the Feb 24 session, CPRX gained 0.33%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Conference date
- March 10, 2026
- Barclays 28th Annual Global Healthcare Conference presentation date
- Presentation time
- 3:30 PM ET
- Scheduled time for Catalyst’s conference presentation
- Webcast replay window
- 30 days
- Replay available in Investors section of company website
Historical Context
-
Announced dates for Q4 and full-year 2025 results release and call.
-
Launched week-long Catalyst Advocacy Scholars Summit with Notre Dame.
-
Planned presentation at 44th Annual J.P. Morgan Healthcare Conference.
-
Participation in Bank of America CNS Therapeutics Virtual Conference.
-
Named to Deloitte Technology Fast 500™ for 249% revenue growth 2021–2024.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CORAL GABLES, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate in the upcoming Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026, being held in Miami, Florida.
Presentation Details
Date: Tuesday, March 10, 2026
Presentation: 3:30 PM ET
Webcast Link
The webcast will be available under the Investors section on the Company's website, www.catalystpharma.com, and a replay will be available for at least 30 days.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., has been recognized by Forbes as one of America’s Most Successful Company in 2023, 2024, and 2025, and on the 2025 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies.
For more information, please visit Catalyst's website at www.catalystpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2024 and its subsequent filings with the U.S. Securities and Exchange Commission (“SEC”), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
Source: Catalyst Pharmaceuticals, Inc.
Contact information: Investor Contact Melissa Kendis, Catalyst Pharmaceuticals, Inc. (305) 420-3200 IR@catalystpharma.com Media Contact Ignacio Guerrero-Ros, Ph.D., Russo Partners, LLC (646) 249-6817 Ignacio.Guerrero-Ros@russopartnersllc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.